Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

$(0.13) $(5.04) $(1.05) $(4.91) ====== ====== ====== ====== Diluted $(0.13) $(5.04) $(1.05) $(4.91) ====== ====== ====== ====== Weighted average common shares outstanding: Basic 304,525 274,313 304,560 249,652 ======= ======= ======= ======= Diluted 304,525 274,313 304,560 249,652 ======= ======= ======= ======= Mylan Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited; in thousands) December 31, 2008 December 31, 2007 ----------------- ----------------- Assets: Current assets: Cash and cash equivalents $557,147 $484,202 Restricted cash 40,309 - Available-for-sale securities 42,260 91,361 Accounts receivable, net 1,164,613 1,132,121 Inventories 1,065,990 1,063,840 Other current assets 304,354 287,777 ------- ------- Total current assets 3,174,673 3,059,301 Intangible assets, net 2,453,161 2,978,706 Goodwill 3,161,580 3,855,971 Other non-current assets 1,620,445 1,459,198 ----
'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... Encyclopedia ... Amazon.com , ... (PRWEB) April 15, 2010 -- The preponderance of autism research shows no correlation between vaccines ... encyK Resource for Parents & Professionals . By retracting the article that first reported the ...
... "sheet-like" nanostructures are commonly employed in biological systems ... have inspired interest in materials such as graphene. ... two-dimensional polymer crystal self-assembled in water to date. ... of biological systems with the durable architecture needed ...
... ... data reporting and ad hoc analysis , ... (PRWEB) April 13, 2010 -- Like many customer-oriented organizations, Maine ... storing its data. The program manages behavioral healthcare for 69,000 recipients in Maine, ...
Cached Biology Technology:Research in Autism Encyclopedia Shows No Link to Children With Autism, Supports Lancet Retraction 2Berkeley Lab scientists create 'molecular paper' 2Maine Medical Center Chooses Business Intelligence Solution from Rapid Insight Inc. 2
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... from the Herman B Wells Center for Pediatric Research at ... family of blood proteins that they hope holds a ... and adults. Their findings may one day help ... and other cancers of the blood. The researchers, led ...
... Swiss scientists conducted intensive studies of the Everest region ... valleys. Around the same time, the Swiss glaciologist Fritz ... above 5000 metres, studying and photographing the Himalayan glaciers. ... white photographs taken by these scientists are of immense ...
... may make us all go a little gooey, but it,s ... researchers at The Australian National University. The study ... ANU suggests that despite fears mothers may have that ... suggest that is true. The findings have been released as ...
Cached Biology News:On the trail of a targeted therapy for blood cancers 2'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 2'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 3Pregnancy not turning minds to mush: Study 2
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
... A thermostable, thermoactive designer enzyme that ... AccuRT RNA PCR enzyme allows reverse ... performed at elevated temperatures (65C), which ... the template and results in highly ...
HLA-DRbeta (DA2)...
Biology Products: